세계 식도 편평상피세포암 시장 예측(-2030년)

Market Overview

The Esophageal Squamous Cell Carcinoma Market is anticipated to register a CAGR) of 8.16% during the review period. The developing expanding commonness of Achalasia expanded research exercises and item endorsements, and rising public mindfulness are driving market development.

The rising commonness of achalasia help market development because achalasia patients have a higher gamble of Esophageal Squamous Cell Carcinoma than everybody. The diary Archives of Throat reports that 9 to 10 individuals for every 100,000 individuals experience achalasia every year.

Besides, as per the Global Organization for Research on Malignant growth, these rates are 15 and multiple times higher, separately, than the gamble of Esophageal Squamous Cell Carcinoma in everyone. Accordingly, expanding pervasiveness of achalasia will straightforwardly influence the market development of worldwide Esophageal Squamous Cell Carcinoma decidedly.

Market Segmentation

The Market segments of Esophageal Squamous Cell Carcinoma, based on diagnosis and treatment, whereas, diagnosis is further segmented into Endoscopy, CT scan, Esophagram, Positron Emission Tomography (PET) and others.

The Esophageal Squamous Cell Carcinoma Market segmentation is based on end user which includes hospitals, specialty centers and others.

Regional Insights

The North America Esophageal Squamous Cell Carcinoma market represented the biggest market share in 2022. This is because of the rising pervasiveness of esophageal disease which is raising the interest for the Esophageal Squamous Cell Carcinoma treatment market. Additionally, the rising speculation by significant vital participants in better treatment options is likewise expected to cultivate North America's market development.

Europe Esophageal Squamous Cell Carcinoma market represents the second-biggest market share because of the rising tendency towards smoke, tobacco, and drink is driving up interest for a high-level treatment choice for Esophageal Squamous Cell Carcinoma. Additionally, rising medical services use is likewise expected to help the development of the market.

The Asia-Pacific Esophageal Squamous Cell Carcinoma market is supposed to develop at a critical offer from 2023 to 2030. This is because of elements, for example, the rising frequency of Esophageal Squamous Cell Carcinoma, and the high populace of tobacco smoking and liquor savoring this area is additionally expected to support the market development. Besides, the Rising actual inertia and unfortunate way of life are additionally expected to support the development of the provincial market. Additionally, China market of Esophageal Squamous Cell Carcinoma is supposed to hold the biggest market offer, and Rest of Asia-Pacific market is normal quickest developing district.

The Rest of the World is sectioned into the Middle East, Africa, and Latin America. The market in the previously mentioned districts is probably going to observe development because of solid epidemiological factors, and further developing medical services offices, expanding mindfulness about sound ways of life.

Major Players

Key Companies in the market of Esophageal Squamous Cell Carcinoma include Hoffmann-La Roche Ltd, AstraZeneca, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Seagen Inc., Eli Lilly and Company, Glaxosmithkline Plc, Novartis AG, Beijing Shenzhou, Cell Biotechnology Group Co., Ltd., and Jacobio Pharmaceuticals Group Co., Ltd.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF ACHALASIA
  • 4.2.2 INCREASED RESEARCH ACTIVITIES AND PRODUCT APPROVALS
  • 4.2.3 RISING PUBLIC AWARENESS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF TREATMENT
  • 4.3.2 SIDE EFFECTS OF ESOPHAGEAL CANCER DRUGS
• 4.4 OPPORTUNITIES
  • 4.4.1 RISE IN CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
  • 5.3.1 IMPACT ON DEMAND
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON MARKET PLAYERS)
• 5.4 TOTAL NUMBER OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS, BY REGION
• 5.5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENT FORECAST, (2018-2024)
• 5.6 STANDARD OF CARE (SOC) FOR THE TREATMENT
  • 5.6.1 STANDARD OF CARE (SOC) FOR SURGERY:
  • 5.6.2 STANDARD OF CARE (SOC) FOR CHEMOTHERAPY:
  • 5.6.3 STANDARD OF CARE (SOC) FOR RADIOTHERAPY:
  • 5.6.4 STANDARD OF CARE (SOC) FOR THE IMMUNOTHERAPY:
  • 5.6.5 STANDARD OF CARE (SOC) FOR OTHER TREATMENTS

6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY DIAGNOSIS & TREATMENT

• 6.1 OVERVIEW
• 6.2 DIAGNOSIS
  • 6.2.1 ENDOSCOPY
  • 6.2.2 CT SCAN
  • 6.2.3 ESOPHAGRAM
  • 6.2.4 POSITRON EMISSION TOMOGRAPHY (PET)
  • 6.2.5 OTHERS
• 6.3 TREATMENT
  • 6.3.1 SURGERY
  • 6.3.2 CHEMOTHERAPY
  • 6.3.3 RADIOTHERAPY
  • 6.3.4 IMMUNOTHERAPY
  • 6.3.5 OTHERS

7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY END USER

• 7.1 OVERVIEW
  • 7.1.1 HOSPITALS
  • 7.1.2 SPECIALTY CENTERS
  • 7.1.3 OTHERS

8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION

• 8.1 GLOBAL
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 UK
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 AUSTRALIA
  • 8.4.5 SOUTH KOREA
  • 8.4.6 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 AFRICA
  • 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
• 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.5.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
• 9.6 FINANCIAL MATRIX
  • 9.6.1 SALES (USD MILLION), 2021
  • 9.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

• 10.1 F. HOFFMANN-LA ROCHE LTD
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 ASTRAZENECA
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
  • 10.3.1 COMPANY OVERVIEWS
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 SEAGEN INC.
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 ELI LILLY AND COMPANY
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGIES
• 10.6 GLAXOSMITHKLINE PLC
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 NOVARTIS AG
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS